Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 65 results found. Search for [ Mylan CEO ]

Results 1 to 21 of 65
PB Jayakumar
July 8, 2020
Various medical shops have been telling buyers that the medicine is in short supply but can be made available If they are ready to pay a premium, DCGI has been informed


BusinessToday.In
June 4, 2020
A Gilead spokesperson told the daily that the manufacturers have been given the authority to set their own prices for the drug


BusinessToday.In
May 15, 2020
Cipla's net profit during the March quarter of FY20 took a beating on account of the coronavirus pandemic. The company posted a 33 per cent decline in consolidated net profit during the quarter ended March 2020


BusinessToday.In
April 29, 2020
Stocks to watch today on April 29: Axis Bank, Atul, JK Paper, NLC India, L&T, PNB Housing, Biocon, Thomas Cook among others are the top stocks to watch out for in Wednesday's trading session


Aprajita Sharma
New Delhi, April 27, 2020
Experts believe there was already a visible turnaround in the pharma sector, both on the domestic as well as on the exports side even before any traces of COVID-19


E Kumar Sharma
January 10, 2020
True North will invest Rs 536.25 crore for a 2.44 per cent minority stake in Biocon Biologics India, taking its value to Rs 21,450 crore, or around $3 billion


E Kumar Sharma
New Delhi, January 1, 2020
Biosimilars are a different ball game -- more complex and more expensive, essentially because biotech drugs, by their very nature, require understanding of living organisms


BusinessToday.In
December 3, 2019
Ogivri will be launched at a competitive discount for customers to help ensure increased access to treatment for thousands of HER2-positive breast and gastric cancer patients, said Biocon


E Kumar Sharma
New Delhi, November 25, 2019
A number of biologics with huge markets are going off-patent in the US. Do Indian pharmaceutical companies have it in them to play this high-cost, high-risk game of launching biosimilars?


PTI
November 18, 2019
The significant violations included failure to have adequate written procedures for the receipt, identification, testing and handling of raw materials


BusinessToday.In
New Delhi, September 24, 2019
According to Biocon Biologics CEO Christiane Hamacher, the high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide


PTI
August 16, 2019



PTI
May 7, 2019



E Kumar Sharma
New Delhi, February 14, 2019
Despite no big product launches in the US last year, Natco Pharma gained from its strategy of focussing on a few big products. It now hopes to build on this.


PB Jayakumar
New Delhi, November 26, 2018
Market changes and increased regulatory oversight in the US have hurt Lupin, but India's third-biggest drug maker is making efforts to come back.


E. Kumar Sharma
New Delhi, October 29, 2018
Strides Pharma Science attributes its underwhelming performance to a confluence of headwinds and execution challenges.


PB Jayakumar
New Delhi, June 28, 2018
Enbrel had global brand sales of approximately $11.6 billion for the 12 months ending December 31, 2017, according to IQVIA.


PTI
June 7, 2018



E. Kumar Sharma
New Delhi, January 10, 2018
By following the strategy of doing a few things well, V.C. Nannapaneni has helped Natco Pharma carve out a space for itself.


PTI
December 29, 2017



PAGES 1 OF 4  1234